A comparative study in efficacy and safety of 0.1% tacrolimus and 0.05%
clobetasol propionate ointment in discoid lupus erythematosus by modified
cutaneous lupus erythematosus disease area and severity index.
Author(s): Pothinamthong P, Janjumratsang P.
Affiliation(s): The Institute of Dermatology, Ministry of Public Health, Bangkok, Thailand.
Thedoc_chai@hotmail.com
Publication date & source: 2012, J Med Assoc Thai. , 95(7):933-40
OBJECTIVE: To compare the efficacy and safety between 0.1% Tacrolimus ointment
twice a day and 0.05% clobetasol propionate.
MATERIAL AND METHOD: Twenty-one Thai patients 18 to 60 years old with DLE lesions
on both right and left sides of the body, without SLE, were included in the
present study. Each patient was randomly allocated to determine the use of one
side for twice-daily 0.1% topical tacrolimus ointment and the other side for
once-daily 0.05% clobetasol propionate ointment for six weeks. Clinical outcomes
were evaluated by modified cutaneous lupus erythematosus disease area and
severity index (CLASI) and global assessment score for patient efficacy
evaluation.
RESULTS: Disease activity score were significantly decreased from baseline in
both groups but clobetasol had better efficacy (p < 0.05). No significant change
in disease damage score between the two groups. Both drugs were well tolerated.
Transient pruritus and burning sensation were found in the tacrolimus group.
Telangiectasia and acneiform eruption were found in the clobetasol group.
CONCLUSION: The present study proved the efficacy of twice-daily tacrolimus and
once-daily clobetasol treatment for DLE lesion. Clobetasol has significantly
higher efficacy and tacrolimus may be an alternative treatment.
|